

pharmacia Corporation

[View the current pharmacia Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8253-pharmacia+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/8253-pharmacia+Corporation.html>)

Contact Details:

700 chesterfield parkway north
st. louis
MO
63198
United States of America

Tel: 636-737-7295

Fax: 636-737-6480

Email: gerald.f.casperson@stl.monsanto.com

Pharmacia is a top-tier global pharmaceutical company, with a leading agricultural subsidiary. We have built a portfolio of outstanding products, led by our key growth drivers: CELEBREX® (celecoxib capsules), CAMPTOSAR® (irinotecan hydrochloride injection), XALATAN® (latanoprost ophthalmic solution), DETROL®LA (tolterodine tartrate extended release capsules), and ZYVOX™ (linezolid injection, tablets, and for oral suspension).

Pharmacia's innovative medicines and other products save lives and enhance health and wellness.

Pharmacia's 59,000 people in more than 60 countries work together with many diverse stakeholders to bring these benefits to people around the world, and to create new health solutions for the future.

Recent Publications by pharmacia Corporation:



- [Synthesis of \(-\)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates.](#)
*PNU-286607 is the first member of a promising, novel class of...*13th June, 2009
Infectious Diseases Medicinal Chemistry, Pharmacia Corporation, 301- J Am Chem Soc. 2009 Mar 25;131(11):3991-7. ([DOI Direct Link](#))
- [Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.](#)
*By using a detergent-washed membrane preparation, the interaction of the...*21st April, 2009
Pharmacia Corp., Kalamazoo, Michigan 49001, USA.- Antimicrob Agents Chemother. 2009 Feb;53(2):496-504. Epub 2008 Dec 1. ([DOI Direct Link](#))
- [Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.](#)
*QPT-1 was discovered in a compound library by high-throughput screening...*31st January, 2009
Infectious Diseases Biology and Medicinal Chemistry, Pharmacia- Antimicrob Agents Chemother. 2008 Aug;52(8):2806-12. Epub 2008 Jun 2. ([DOI Direct Link](#))

- [Resistance mapping and mode of action of a novel class of antibacterial anthranilic acids: evidence for disruption of cell wall biosynthesis.](#)
*OBJECTIVES: The aim of this study was to characterize the mechanism of...*7th November, 2008
 Infectious Diseases Biology, Pharmacia Corporation, 301 Henrietta Street,- J Antimicrob Chemother. 2008 Oct;62(4):720-9. Epub 2008 Jun 19. ([DOI Direct Link](#))
- [Nimodipine: test your drug IQ.](#)
*Find out how this calcium channel blocker treats cerebral vasospasm after...*18th September, 2008
 Hospice Pharmacia, Division of excelleRx, Philadelphia, PA, USA.- Nursing. 2008 Jul;38(7):56cc1-2. ([DOI Direct Link](#))
- [Chromatofocusing.](#)
*This unit discusses choice of chromatofocusing medium and buffers,...*17th June, 2008
 Pharmacia Biotech, Piscataway, New Jersey, USA.- Curr Protoc Protein Sci. 2001 May;Chapter 8:Unit8.5. ([DOI Direct Link](#))
- [Hydrophobic-interaction chromatography.](#)
*This unit discusses the important parameters in designing and optimizing a...*17th June, 2008
 Pharmacia Biotech, Piscataway, New Jersey, USA.- Curr Protoc Protein Sci. 2001 May;Chapter 8:Unit8.4. ([DOI Direct Link](#))
- [Gel-filtration chromatography.](#)
*Three basic protocols are provided in this unit, corresponding to the...*17th June, 2008
 Amersham Pharmacia Biotech AB, Uppsala, Sweden.- Curr Protoc Protein Sci. 2001 May;Chapter 8:Unit8.3. ([DOI Direct Link](#))
- [Ion-exchange chromatography.](#)
*This unit outlines the basic steps in planning and carrying out...*17th June, 2008
 Amersham Pharmacia Biotech, Piscataway, New Jersey, USA.- Curr Protoc Protein Sci. 2001 May;Chapter 8:Unit8.2. ([DOI Direct Link](#))
- [Overview of conventional chromatography.](#)
*The key to success in purification of any protein is developing the right...*17th June, 2008
 Pharmacia Biotech, Piscataway, New Jersey, USA.- Curr Protoc Protein Sci. 2001 May;Chapter 8:Unit8.1. ([DOI Direct Link](#))
- [Bisphosphonates: A review of their novel anti-inflammatory properties and potential for the treatment of rheumatoid arthritis.](#)
*Bisphosphonates (BP) are synthetic pyrophosphates with a stable P-C-P bond...*10th May, 2008
 Pharmacia and Upjohn, Henrietta St, Kalamazoo, MI 49001, USA.- IDrugs. 1998 Aug;1(4):429-41.
- [One-dimensional electrophoresis using nondenaturing conditions.](#)
*Nondenaturing or "native" electrophoresis--i.e., electrophoresis in the...*9th May, 2008
 Hoefer Pharmacia Biotech, San Francisco, California, USA.- Curr Protoc Protein Sci. 2001 May;Chapter 10:Unit 10.3. ([DOI Direct Link](#))
- [One-dimensional SDS gel electrophoresis of proteins.](#)
*Electrophoresis is used to separate complex mixtures of proteins, to...*9th May, 2008
 Hoefer Pharmacia Biotech, San Francisco, California, USA.- Curr Protoc Protein Sci. 2001 May;Chapter 10:Unit 10.1. ([DOI Direct Link](#))
- [Overview of digital electrophoresis analysis.](#)
*Gel electrophoresis has become a ubiquitous method in molecular biology...*19th March, 2008
 Amersham Pharmacia Biotech, San Francisco, California, USA.- Curr Protoc Mol Biol. 2004 May;Chapter 10:Unit 10.5. ([DOI Direct Link](#))
- [Gel-filtration chromatography.](#)
*Gel filtration (GF) chromatography separates proteins solely on the basis...*28th February, 2008
 Amersham Pharmacia Biotech AB, Uppsala, Sweden.- Curr Protoc Mol Biol. 2001 May;Chapter 10:Unit 10.9. ([DOI Direct Link](#))

Press Releases on pharmacia Corporation:

Centene Corporation to Present at Upcoming Healthcare Conferences	6th November, 2009	Centene Corporation	ST. LOUIS, Nov. 6 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at two upcoming healthcare conferences over the next few weeks. Next week, at the
Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results	6th November, 2009	BioSpecifics Technologies Corp.	-- In its September 3, 2009 edition, The New England Journal of Medicine published data from the pivotal CORD I Phase III clinical trial of XIAFLEX for the treatment of Dupuytren
"AIM"ING FOR BETTER ASTHMA CARE	6th November, 2009	Schering Corporation	Asthma Insight and Management (AIM) Survey Reveals Unmet Needs in Current Asthma Care in the United States Asthma is a chronic condition affecting more than 22 million adults and children in
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution	6th November, 2009	Caraco Pharmaceutical Laboratories, Ltd.	DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US
Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants	6th November, 2009	Myriant Technologies LLC	QUINCY, Mass., Nov. 6 /PRNewswire/ -- Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and

BioNews Results for pharmacia Corporation



- [Schering-Plough Chairman and CEO Fred Hassan Joins Time Warner's Board of Directors](#)
NewsBlaze: Oct 30 2009 7:30AM Matching: pharmacia
- [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)

- Pharma Live: Oct 30 2009 11:39PM Matching: pharmacia*
- [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
Pharmacy Choice: Oct 30 2009 10:57PM Matching: pharmacia
 - [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
Freshnews.com: Oct 30 2009 6:50PM Matching: pharmacia
 - [Pediatric Exclusivity Granted](#)
FDA: Oct 30 2009 6:38PM Matching: pharmacia
 - [World's Scariest Stocks: Pfizer](#)
Motley Fool: Oct 30 2009 4:04PM Matching: pharmacia
 - [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
Individual.com: Oct 30 2009 3:58PM Matching: pharmacia
 - [World's Scariest Stocks: Pfizer](#)
Motley Fool via MSN Money: Oct 30 2009 3:53PM Matching: pharmacia
 - [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
Reuters: Oct 30 2009 3:52PM Matching: pharmacia
 - [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
Yahoo! Canada: Oct 30 2009 3:38PM Matching: pharmacia
 - [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
PR inside: Oct 30 2009 3:29PM Matching: pharmacia
 - [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
RBC Dain Rauscher: Oct 30 2009 3:27PM Matching: pharmacia
 - [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
Business Wire via Yahoo!: Oct 30 2009 3:15PM Matching: pharmacia
 - [ERYtech Pharma Reinforces its Supervisory Board and its Scientific Board](#)
Business Wire: Oct 30 2009 3:14PM Matching: pharmacia
 - [::: ERYtech Pharma reinforces its Supervisory Board and its Scientific Board](#)
Biotech Intelligence: Oct 30 2009 6:10AM Matching: pharmacia

pharmacia Corporation Clinical Trials:



- [A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin \(450 Mg\) or Rifabutin \(300 Mg\) or Placebo](#)

pharmacia Corporation Patents:



- 7208490- [Tricyclic tetrahydroquinoline antibacterial agents](#)
- 7244755- [Hydroxypropylamines](#)

- [7247627- Salts and polymorphs of a pyrrole-substituted indolinone compound](#)
- [7247706- Double mutant alpha-7 nicotinic acetylcholine receptors](#)
- [7256189- 3-\(4-amidopyrrol-2-ylmethylidene\)-2-indolinone der derivatives as protein kinase inhibitors](#)
- [7259266- Benzopyran compounds useful for treating inflammatory conditions](#)
- [7262208- Hydroxypropyl amides for the treatment of Alzheimer's disease](#)
- [7276503- Method of treating chronic fatigue syndrome](#)
- [7291738- Therapeutic compounds](#)
- [7309811- Transgenic mice knockouts of BACE-1](#)
- [7312333- Retroviral protease inhibitors](#)
- [7244725- Acetyl 2-hydroxy-1, 3-diaminoalkanes](#)
- [7241762- Method of treating peripheral neuropathy](#)
- [7208591- G protein-coupled receptor-like receptors and modulators thereof](#)
- [7211686- Process for making optically active .alpha.-amino ketones and selected novel optically active .alpha.-amino ketones](#)
- [7214715- Compounds to treat Alzheimer's disease](#)
- [7220434- Dual-release compositions of a cyclooxygenase-2 inhibitor](#)
- [7220867- Solid-state form of celecoxib having enhanced bioavailability](#)
- [7229965- Use of growth hormone in low dose](#)
- [7232894- Method for the production of recombinant peptides with a low amount of trisulfides](#)
- [7232930- Compounds and methods for preparing methanesulfonamides](#)
- [7235655- Processes to prepare eplerenone](#)
- [7238507- Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase](#)
- [7312360- Substituted hydroxyethylamines](#)
- [7317011- Method of treating peripheral neuropathy](#)
- [7320996- Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer](#)
- [7420061- Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors](#)
- [7435832- Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof](#)
- [7442691- Macrocycles useful in the treatment of alzheimer's disease](#)
- [7445641- Biomaterials modified with superoxide dismutase mimics](#)
- [7452913- Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors](#)
- [7456269- Alzheimer's disease secretase, APP substrates thereof, and uses thereof](#)
- [7476391- Anti-bacterial vaccine compositions](#)
- [7498436- Substituted hydroxyethylamines](#)
- [7572924- Pyrrole substituted 2-indolinone protein kinase inhibitors](#)
- [7582756- 3-\(4-amidopyrrol-2-ylmethylidene\)-2-indolinone derivatives as protein kinase inhibitors](#)
- [7378511- Alzheimer's disease secretase, APP substrates therefor, and uses therefor](#)
- [7377894- Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules](#)
- [7322965- Infection-resistant medical devices](#)
- [7338953- Method of treating chronic fatigue syndrome](#)
- [7338965- 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines](#)
- [7351738- Substituted ureas and carbamates](#)
- [7354724- Drosophila G protein coupled receptors, nucleic acids, and methods related to the same](#)
- [7354943- Statine derivatives for the treatment of Alzheimer's disease](#)
- [7358264- Statine derivatives for the treatment of Alzheimer's disease](#)
- [7364866- Drosophila G protein coupled receptors, nucleic acids, and methods related to the same](#)
- [7368536- Alzheimer's disease secretase, APP substrates therefor, and uses therefor](#)
- [7375187- Alzheimer's disease secretase, APP substrates therefor, and uses therefor](#)
- [7605157- Tricyclic tetrahydroquinoline antibacterial agents](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

